Key result
New effective therapies for relapsing-remitting multiple sclerosis have shifted the treatment paradigm from partial response to remission, necessitating accurate measures of disease control.
Why the study?
The development of new effective therapies for relapsing-remitting MS has increased the need for accurate measures to evaluate therapeutic impact and shift treatment goals from partial response to remission.
Key points are not available for this paper at this time.
Design
Other
The advent of new effective therapies for relapsing-remitting (RR) multiple sclerosis (MS) has increased the expectations for disease control. This has made it crucial to use measures able to accurately evaluate the impact of therapeutic intervention, shifting the treatment paradigm of MS from partial response to remission.1
No takes yet. Share an insight, caveat, or question.
Stefano et al. (2015) studied this question. New effective therapies for relapsing-remitting multiple sclerosis have shifted the treatment paradigm from partial response to remission, necessitating accurate measures of disease control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: